Solitary Bone Plasmacytoma: A Case Report from a Private Specialist Referral Centre in Port Harcourt
Article Sidebar
Main Article Content
Abstract
Introduction: Multiple myeloma is uncommon in Nigeria with about 10% of cases presenting with paraplegia. The aim of this study was to provide a description of a case report of spinal myeloma seen and treated at a private specialist referral hospital in Port Harcourt from 2016 to 2023.
Case Presentation: A 56-year-old male professional diver presented in 2016 with complaint of progressive low back pain of two years duration of insidious-onset and associated with paraparesis. Physical examination and laboratory investigation findings were in-keeping with a diagnosis of solitary bone plasmacytoma of the spine. Patient responded well to novel systemic chemotherapy
and has been on out-patient follow-up.
Conclusion: Plasmacytoma can occur in any part of the body, and spinal plasmacytoma affecting the spine can cause paraparesis. Prompt diagnosis and appropriate treatment can improve disease free survival, and use of novel systemic chemotherapy is a viable option.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Solly S. Remarks on the pathology of mollities ossium; with cases. Medico-chirurgical transactions. 1844; 27:435-461.
Ribatti D. A historical perspective on milestones in multiple myeloma research. European journal of haematology. 2018; 100(3):221-228
Kyle RA, Steensma DP. History of multiple myeloma. Multiple myeloma: Springer; 2011. p. 3-23.
Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, et al. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology. 2019;15(13):1411-428.
Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med. Sci. 2021; 9(1); 3. https://doi.org/10.3390/medsci9010003
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90.
Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC cancer. 2021;21(1):1-13.
Veres IA, Cardos IA. Multiple Myeloma: Focus On International Epidemiology Literature. Acta Medica Transilvanica. 2022; 27(1): 25-27.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. 2010;127(12):2893-2917.
Hemminki K, Försti A, Houlston R, Sud A. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. International Journal of Cancer. 2021;149(12):1980-1996.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al., editors. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proceedings; 2003: 78 (1):21-33.
Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology. 2004; 231(1):11-23.
Madu A, Ocheni S, Nwagha T, Ibegbulam O, Anike U. Multiple myeloma in Nigeria: an insight to the clinical, laboratory features, and outcomes. Nigerian journal of clinical practice. 2014;17(2):212-217.
Omoti CE, Omuemu CE. Multiple myeloma: a ten-yearstudy of survival and therapy in a developing nation. JPMA. 2007. 57(7): 341-344.
Nwabuko OC, Igbigbi EE, Chukwuonye II, Nnoli MA. Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. Cancer Management and Research. 2017; 9:189-196.
Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMGCONCEPT trial. Leukemia. 2022; 36(3):885-888.
Susanibar Adaniya S, Stadtmauer EA, Cohen AD. CAR T cell therapy for multiple myeloma: What have we learned? Leukemia. 2022; 36(6):1481-1484.
Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, et al. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 2022; 28(9):1759-1764.
Kanapuru B, Fernandes LL, Fashoyin-Aje LA, Baines AC, Bhatnagar V, Ershler R, et al. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood advances. 2022; 6(6):1684-1691.
Ebied AM, Elmariah H, Cooper-DeHoff RM. New drugs approved in 2021. The American Journal of Medicine. 2022; 135(7):836-839.
Grammatico S, Scalzulli E, Petrucci MT. Solitary plasmacytoma. Mediterranean journal of hematology and infectious diseases. 2017; 9(1): e2017052. doi: 10.4084/MJHID.2017.052. PMC5584766
Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Current treatment options in oncology. 2002; 3:255-259.doi.org/10.1007/s11864-002-0015-2
Zhao Y, Han L, Li D, Wang Z. Solitary bone plasmacytoma of spine with involvement of intervertebral disk: a case report and literature review. Skeletal Radiology. 2024;1-6.DOI: https://doi.org/10.1007/s00256-024-04566-x. PMID: 38231261
Channappa TS, Shivkumar HB, Singh SP. Malignant Lesion of Clavicle. Journal of Orthopaedic Diseases and Traumatology. 2023 Sep 1;6(3):269-73. DOI: 10.4103/jodp.jodp_23_23
Bernardi S, Bianchi S, Lupi E, Gerardi D, Macchiarelli G, Varvara G. Plasmacytoma in the maxillary jaw: A diagnostic and therapeutic challenge. Hematol. Rep. 2024, 16(1), 22-31; https://doi.org/10.3390/hematolrep16010003
Ibikunle A, Taiwo A, Braimah R, Adeyemi M. Solitary plasmacytoma of the mandible: Report of a rare case. International Biological and Biomedical Journal. 2018;4(1):67-71.
Obimakinde OS, Taiwo OJ, Lawal AO, Adisa AO, Okoje VN, Arotiba JT. Solitary plasmacytoma of the zygoma in a 70-year-old Nigerian: A case report and review of literature. International Journal of Otolaryngology and Head & Neck Surgery. 2014; 3(4): 195-199. DOI:10.4236/ijohns.2014.34036
Nottidge TE, Nottidge BA, Ekrikpo UE. Prevalence and predictors of low back pain in a Southern Nigerian hospital. Ann Afr Med. 2019; 18(3):167-172. doi: 10.4103/aam.aam_59_18. PMID: 31417018; PMCID: PMC6704812.
Birabi BN, Dienye PO, Ndukwu GU. Prevalence of low back pain among peasant farmers in a rural community in South South Nigeria. Rural and remote health. 2012;12(3):1-10. PMID: 22934910.
Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, et al. Prevalence of and screening for serious spinal pathology in patients presenting to primary care settings with acute low back pain. Arthritis Rheum. 2009; 60:3072–3080.
McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. Journal of spinal disorders. 1989; 2(2):69-74.
Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018; 11(1):10. doi: 10.1186/s13045-017-0549-1. PMID: 29338789; PMCID: PMC5771205.
Mheidly K, De La Chapelle TL, Hunault M, Benboubker L, Benchalal M, Moreau P, de Materre AB, Decaux O, Laribi K. New insights in the treatment of patients with solitary bone plasmacytoma. Leukemia & Lymphoma. 2019; 60(11): 2810-2813, DOI: 10.1080/10428194.2019.1605067.
Fregonese B, Dreyfuss A, Lee J, Imber BS, Yahalom J, Hajj C. Predictors of Response to Radiation Therapy and of Progression to Multiple Myeloma in Patients with Solitary Bone and Extramedullary Plasmacytomas. Blood. 2022;140(Supplement 1):10104-5. doi: https://doi.org/10.1182/blood-2022-169633
Sharpley FA, Neffa P, Panitsas F, Eyre TA, Kothari J, Subesinghe M, Cutter D, Szor RS, Martinez GA, Rocha V, Ramasamy K. Correction: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. Plos one. 2019; 4(11):e0225184.
doi.org/10.1371/journal.pone.0225184
Elsayad K, Oertel M, König L, Hüske S, Le Ray E, Meheissen MAM, Elsaid AA, Elfaham E, Debus J, Kirova Y, Herfarth K, Eich HT. Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis. Cancers (Basel). 2020; 12(3):676. doi: 10.3390/cancers12030676. PMID: 32183106; PMCID: PMC7139814.
Mheidly K, Lamy T, Escoffre M, Hunault M, Benboubker L, Esvan M, Benchalal M, Moreau P, Decaux O. Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma. Blood. 2016; 128(22):4514. doi: https://doi.org/10.1182/blood.V128.22.4514.4514